Abstract
Quantitative unit operation models for the optimization and refinement of modern late-stage biopharmaceutical drug manufacturing processes have recently attracted increasing attention. The supplementary benefits of these models include increased process robustness and control in combination with a more stringent design of the bioprocess due to a reduced number of exploratory experiments. In addition to unit operations, further efforts also focus on digital bioprocess replicas, which are straightforward combinations of unit operation and process models from inoculum to the fill and finish phase. In this review, we shed more light on digital bioprocess replicas in addition to standard unit operation models and discuss their strengths and weaknesses. We comment on the current usage of these approaches for late stage processes and outline the associated benefits, challenges and limitations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
